Teva Pharmaceutical Industries Limited’s ProAir(R) HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir® HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age. Previously, ProAir HFA had been indicated for use in patients aged 12 and older.

MORE ON THIS TOPIC